653
Views
24
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the treatment of Dravet syndrome

ORCID Icon, ORCID Icon, & ORCID Icon
Pages 261-269 | Received 22 Aug 2018, Accepted 23 Nov 2018, Published online: 04 Dec 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Antonella Riva, Gianluca D’Onofrio, Elisabetta Amadori, Domenico Tripodi, Ganna Balagura, Valentina Iurilli, Maria Stella Vari, Alberto Verrotti & Pasquale Striano. (2022) Current and promising therapeutic options for Dravet syndrome. Expert Opinion on Pharmacotherapy 23:15, pages 1727-1736.
Read now
Alberto Verrotti & Pasquale Striano. (2021) Novel therapeutic options for Dravet and Lennox-Gastaut syndrome. Expert Review of Neurotherapeutics 21:11, pages 1191-1194.
Read now
Barbara Miziak & Stanisław Czuczwar. (2021) Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome. Expert Opinion on Drug Discovery 16:5, pages 579-593.
Read now
Adam Strzelczyk & Susanne Schubert-Bast. (2020) Therapeutic advances in Dravet syndrome: a targeted literature review. Expert Review of Neurotherapeutics 20:10, pages 1065-1079.
Read now
Francesco Brigo, Pasquale Striano & Vicenzo Belcastro. (2019) A reappraisal of atypical absence seizures in children and adults: therapeutic implications. Expert Opinion on Pharmacotherapy 20:17, pages 2115-2120.
Read now
Catherine Chiron. (2019) Stiripentol for the treatment of seizures associated with Dravet syndrome. Expert Review of Neurotherapeutics 19:4, pages 301-310.
Read now

Articles from other publishers (18)

Robert Lersch, Rawan Jannadi, Leonie Grosse, Matias Wagner, Marius Frederik Schneider, Celina von Stülpnagel, Florian Heinen, Heidrun Potschka & Ingo Borggraefe. (2022) Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome. The Neuroscientist 29:6, pages 732-750.
Crossref
Gianluca Dini, Eleonora Tulli, Giovanni Battista Dell’Isola, Elisabetta Mencaroni, Giuseppe Di Cara, Pasquale Striano & Alberto Verrotti. (2022) Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine. Frontiers in Pharmacology 13.
Crossref
Francesca MarcheseMaria Stella VariGanna BalaguraAntonella RivaVincenzo SalpietroAlberto VerrottiRita CitraroSimona LattanziCarlo MinettiEmilio RussoPasquale Striano. (2022) An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy. Cannabis and Cannabinoid Research 7:2, pages 199-206.
Crossref
Adam Strzelczyk & Susanne Schubert-Bast. (2022) A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. CNS Drugs 36:3, pages 217-237.
Crossref
Elena Cardenal‐Muñoz, Stéphane Auvin, Vicente Villanueva, J. Helen Cross, Sameer M. Zuberi, Lieven Lagae & José Ángel Aibar. (2021) Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe. Epilepsia Open 7:1, pages 11-26.
Crossref
Scott C. Baraban. (2021) A zebrafish-centric approach to antiepileptic drug development. Disease Models & Mechanisms 14:7.
Crossref
Antonella Fattorusso, Sara Matricardi, Elisabetta Mencaroni, Giovanni Battista Dell'Isola, Giuseppe Di Cara, Pasquale Striano & Alberto Verrotti. (2021) The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Frontiers in Neurology 12.
Crossref
Kumar Sannagowdara & Nadir Khan. (2021) Medical Management in Focal versus Generalized Epilepsy. Journal of Pediatric Epilepsy 10:02, pages 081-087.
Crossref
Valentina Satta, Cristina Alonso, Paula Díez, Soraya Martín-Suárez, Marta Rubio, Juan M. Encinas, Javier Fernández-Ruiz & Onintza Sagredo. (2021) Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments. Frontiers in Molecular Neuroscience 13.
Crossref
Ganna Balagura, Marta Cacciatore, Eleonora A. Grasso, Pasquale Striano & Alberto Verrotti. (2020) Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome. CNS Drugs 34:10, pages 1001-1007.
Crossref
Zhou Han, Chunling ChenAnne ChristiansenSophina JiQian Lin, Charles AnumonwoChante Liu, Steven C. Leiser MeenaIsabel AznarezGene LiauLori L. Isom. (2020) Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome . Science Translational Medicine 12:558.
Crossref
Wolfgang Löscher, Heidrun Potschka, Sanjay M. Sisodiya & Annamaria Vezzani. (2020) Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacological Reviews 72:3, pages 606-638.
Crossref
James W. Wheless, Stephen P. Fulton & Basanagoud D. Mudigoudar. (2020) Dravet Syndrome: A Review of Current Management. Pediatric Neurology 107, pages 28-40.
Crossref
Alberto Verrotti, Simona Lattanzi, Francesco Brigo & Gaetano Zaccara. (2020) Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy & Behavior 104, pages 106939.
Crossref
Stephen F. Traynelis, Dennis Dlugos, David Henshall, Heather C. Mefford, Michael A. Rogawski, Kevin J. Staley, Penny A. Dacks, Vicky Whittemore & Annapurna Poduri. (2020) Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Currents 20:1_suppl, pages 23S-30S.
Crossref
Guy A. Higgins, Paul J. Fletcher & William R. Shanahan. (2020) Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacology & Therapeutics 205, pages 107417.
Crossref
Leonardo B. Silenieks, Nicole K. Carroll, Annalise Van Niekerk, Emily Van Niekerk, Colleen Taylor, Neil Upton & Guy A. Higgins. (2019) Evaluation of Selective 5-HT 2C Agonists in Acute Seizure Models . ACS Chemical Neuroscience 10:7, pages 3284-3295.
Crossref
E. D. Belousova & A. A. Sharkov. (2019) Difficulties in the diagnosis, prognosis and treatment of genetic epileptic encephalopathies: the view of a neurologist. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:11, pages 34.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.